 Stacey Martiniano
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 36 | 2025 | 1114 | 7.720 |
Why?
| | Mycobacterium Infections, Nontuberculous | 17 | 2025 | 363 | 4.830 |
Why?
| | Nontuberculous Mycobacteria | 11 | 2023 | 205 | 3.280 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 5 | 2023 | 329 | 1.250 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 62 | 1.250 |
Why?
| | Neonatal Screening | 4 | 2023 | 169 | 1.030 |
Why?
| | Ethambutol | 1 | 2021 | 26 | 0.720 |
Why?
| | Rifampin | 1 | 2021 | 84 | 0.690 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.690 |
Why?
| | Azithromycin | 1 | 2021 | 100 | 0.670 |
Why?
| | Mycobacterium abscessus | 4 | 2025 | 117 | 0.670 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 316 | 0.630 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 88 | 0.620 |
Why?
| | Sputum | 3 | 2020 | 311 | 0.590 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 184 | 0.590 |
Why?
| | Genetic Testing | 1 | 2021 | 460 | 0.580 |
Why?
| | Clofazimine | 1 | 2017 | 15 | 0.540 |
Why?
| | Algorithms | 2 | 2021 | 1704 | 0.520 |
Why?
| | Aminophenols | 3 | 2024 | 156 | 0.480 |
Why?
| | Coinfection | 4 | 2020 | 137 | 0.470 |
Why?
| | Humans | 38 | 2025 | 137585 | 0.410 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 141 | 0.390 |
Why?
| | Precision Medicine | 1 | 2016 | 429 | 0.380 |
Why?
| | Mutation | 5 | 2023 | 3958 | 0.370 |
Why?
| | Pneumonia | 1 | 2017 | 639 | 0.350 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 361 | 0.330 |
Why?
| | Lung Diseases | 1 | 2016 | 767 | 0.330 |
Why?
| | Disease Management | 1 | 2014 | 628 | 0.320 |
Why?
| | Infant, Newborn | 6 | 2024 | 6079 | 0.310 |
Why?
| | Retrospective Studies | 9 | 2022 | 15657 | 0.310 |
Why?
| | Pseudomonas aeruginosa | 3 | 2021 | 352 | 0.270 |
Why?
| | Morbidity | 2 | 2019 | 324 | 0.250 |
Why?
| | Phage Therapy | 1 | 2025 | 15 | 0.230 |
Why?
| | Meconium Ileus | 1 | 2024 | 5 | 0.230 |
Why?
| | Child | 8 | 2022 | 21935 | 0.230 |
Why?
| | Leprostatic Agents | 1 | 2022 | 5 | 0.200 |
Why?
| | Fetal Diseases | 1 | 2024 | 173 | 0.200 |
Why?
| | Delayed Diagnosis | 1 | 2023 | 91 | 0.200 |
Why?
| | Infant | 5 | 2023 | 9465 | 0.190 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.190 |
Why?
| | Quality Improvement | 3 | 2020 | 1178 | 0.190 |
Why?
| | Trypsinogen | 1 | 2021 | 11 | 0.180 |
Why?
| | Adolescent | 7 | 2021 | 21513 | 0.180 |
Why?
| | Indoles | 1 | 2024 | 412 | 0.180 |
Why?
| | Cohort Studies | 4 | 2022 | 5742 | 0.180 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 37 | 0.180 |
Why?
| | Pyrazoles | 1 | 2024 | 423 | 0.180 |
Why?
| | Chloride Channel Agonists | 2 | 2024 | 84 | 0.180 |
Why?
| | Oropharynx | 1 | 2021 | 46 | 0.170 |
Why?
| | Pyridines | 1 | 2024 | 506 | 0.170 |
Why?
| | Bacteriophages | 1 | 2022 | 98 | 0.170 |
Why?
| | Symptom Flare Up | 1 | 2020 | 39 | 0.170 |
Why?
| | Quinolones | 2 | 2024 | 137 | 0.160 |
Why?
| | Specimen Handling | 1 | 2021 | 183 | 0.160 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1066 | 0.160 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 363 | 0.160 |
Why?
| | Antitubercular Agents | 1 | 2021 | 206 | 0.160 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 314 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2025 | 10811 | 0.150 |
Why?
| | Cross-Over Studies | 1 | 2021 | 564 | 0.150 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 110 | 0.150 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 600 | 0.150 |
Why?
| | Infection Control | 1 | 2019 | 167 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.140 |
Why?
| | Risk Factors | 4 | 2019 | 10388 | 0.130 |
Why?
| | Cross Infection | 1 | 2019 | 256 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1809 | 0.130 |
Why?
| | United States | 5 | 2021 | 14841 | 0.130 |
Why?
| | Lipopolysaccharides | 1 | 2020 | 886 | 0.130 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1946 | 0.130 |
Why?
| | Anticoagulants | 1 | 2021 | 664 | 0.130 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 167 | 0.130 |
Why?
| | Anti-Infective Agents | 1 | 2019 | 255 | 0.120 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 390 | 0.110 |
Why?
| | Genetic Therapy | 1 | 2016 | 297 | 0.110 |
Why?
| | Genotyping Techniques | 1 | 2014 | 75 | 0.110 |
Why?
| | Male | 9 | 2025 | 67762 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 496 | 0.100 |
Why?
| | Registries | 1 | 2021 | 2035 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 344 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 399 | 0.100 |
Why?
| | Prospective Studies | 2 | 2025 | 7604 | 0.100 |
Why?
| | Young Adult | 4 | 2020 | 13209 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 80 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2057 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3556 | 0.100 |
Why?
| | Global Health | 1 | 2015 | 386 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 63 | 0.100 |
Why?
| | Decision Making | 1 | 2019 | 900 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 531 | 0.100 |
Why?
| | Female | 8 | 2025 | 73304 | 0.090 |
Why?
| | Prevalence | 1 | 2019 | 2734 | 0.090 |
Why?
| | Child, Preschool | 3 | 2021 | 11074 | 0.090 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 225 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 108 | 0.090 |
Why?
| | Genotype | 1 | 2016 | 1916 | 0.090 |
Why?
| | Adult | 6 | 2025 | 37929 | 0.090 |
Why?
| | Metagenomics | 2 | 2021 | 169 | 0.080 |
Why?
| | Disease Progression | 1 | 2016 | 2757 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5131 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 2531 | 0.060 |
Why?
| | Animals | 2 | 2019 | 36940 | 0.060 |
Why?
| | Genomics | 2 | 2021 | 795 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7635 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2024 | 79 | 0.060 |
Why?
| | Lung | 3 | 2022 | 4060 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 310 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 343 | 0.050 |
Why?
| | Benzodioxoles | 1 | 2024 | 115 | 0.050 |
Why?
| | Quinolines | 1 | 2024 | 178 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 26 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 289 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 327 | 0.040 |
Why?
| | Middle Aged | 2 | 2020 | 33479 | 0.040 |
Why?
| | Aged | 1 | 2017 | 23961 | 0.030 |
Why?
| | Neutrophils | 1 | 2023 | 1238 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1710 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2031 | 0.030 |
Why?
| | Superoxides | 1 | 2013 | 202 | 0.020 |
Why?
| | Pregnancy | 1 | 2024 | 6763 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2804 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 260 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4149 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1774 | 0.020 |
Why?
|
|
Martiniano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|